Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-669899f699-swprf Total loading time: 0 Render date: 2025-05-06T09:22:44.009Z Has data issue: false hasContentIssue false

Chapter 21 - Contraception in Women with Benign Breast Disease and Benign Uterine and Ovarian Conditions

from Section 2A - Sexual and Reproductive Healthcare: Contraception

Published online by Cambridge University Press:  16 January 2024

By
Giovanni Grandi ,
Maria Chiara Del Savio  and
Fabio Facchinetti
Edited by
Johannes Bitzer  and
Tahir A. Mahmood
Johannes Bitzer
Affiliation:
University Women's Hospital, Basel
Tahir A. Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Get access

Summary

Benign breast diseases (BBDs) deserve attention because of their high prevalence, their impact on women’s quality of life (QoL) and, only for some histologic types, their cancerous potential. Fibrocystic breast disease (FBD), recently called “fibrocystic changes,” is the most frequent BBD, diagnosed in 50% of clinically and 90% of histopathologically examined women [1].

Type
Chapter
Information
Textbook of Contraception, Sexual and Reproductive Health , pp. 146 - 153
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Milosevic, ZC, Nadrljanski, MM, Milovanovic, ZM et al. Breast dynamic contrast enhanced MRI: Fibrocystic changes presenting as a non-mass enhancement mimicking malignancy. Radiol Oncol. 2017;51(2):130–6.CrossRefGoogle ScholarPubMed
Dupont, WD, Page, DL, Parl, FF et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med. 1994;331(1):10–15.CrossRefGoogle ScholarPubMed
Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347:1713–22.Google Scholar
Vessey, M, Yeates, D. Oral contraceptives and benign breast disease: An update of findings in a large cohort study. Contraception. 2007;76:418–24.CrossRefGoogle Scholar
Rohan, TE, Miller, AB. A cohort study of oral contraceptive use and risk of benign breast disease. Int J Cancer. 1999;82:191–6.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
Cibula, D, Gompel, A, Mueck, AO et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16(6):631–50.CrossRefGoogle ScholarPubMed
Li, J, Humphreys, K, Ho, PJ et al. Family history, reproductive, and lifestyle risk factors for fibroadenoma and breast cancer. JNCI Cancer Spectr. 2018;2(3):pky051.CrossRefGoogle ScholarPubMed
Faculty of Sexual & Reproductive Healthcare. UK medical eligibility criteria for contraceptive use (UKMEC). London: Faculty of Sexual & Reproductive Healthcare,2016. www.fsrh.org/standards-and-guidance/documents/ukmec-2016.Google Scholar
Centers for Disease Control and Prevention. US medical eligibility criteria for contraceptive use (USCDC). 2016. http://bit.ly/3RhFASx.Google Scholar
World Health Organization. Medical eligibility criteria for contraceptive use. 5th edition. Geneva: World Health Organization, 2015.Google Scholar
McGurgan, P, Taylor, LJ, Duffy, SR et al. Are endometrial polyps from pre-menopausal women similar to post-menopausal women? An immunohistochemical comparison of endometrial polyps from pre- and post-menopausal women. Maturitas. 2006;54:277–84.CrossRefGoogle ScholarPubMed
Cohen, I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94:256–66.CrossRefGoogle ScholarPubMed
Wada-HiraikeE, O, Osuga, Y, Hiroi, H et al. Sessile polyps and pedunculated polyps respond differently to oral contraceptives. Gynecol Endocrinol. 2011;27(5):351–5.CrossRefGoogle Scholar
Meresman, GF, Auge, L, Baranao, RI et al. Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis. Fertil Steril. 2002;77:1141–7.CrossRefGoogle ScholarPubMed
Chowdary, P, Maher, P, Ma, T et al. The role of the Mirena intrauterine device in the management of endometrial polyps: A pilot study. J Minim Invasive Gynecol. 2019;26(7):1297–1302.CrossRefGoogle ScholarPubMed
Vannuccini, S, Luisi, S, Tosti, C et al. Role of medical therapy in the management of uterine adenomyosis. Fertil Steril. 2018;109(3):398–405.CrossRefGoogle ScholarPubMed
Fedele, L, Portuese, A, Bianchi, S et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril. 1997;68:426–9.CrossRefGoogle ScholarPubMed
Critchley, HOD, Wang, H, Kelly, RW et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod. 1998;13:1210–17.CrossRefGoogle ScholarPubMed
Sheng, J, Zhang, WY, Zhang, JP et al. The LNG-IUS study on adenomyosis: A 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009;79:189–93.CrossRefGoogle Scholar
Ozdegirmenci, O, Kayikcioglu, F, Akgul, MA et al. Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis. Fertil Steril. 2011;95:497–502.CrossRefGoogle ScholarPubMed
Shaaban, OM, Ali, MK, Sabra, AM et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: A randomized clinical trial. Contraception. 2015;92(4):301–7.CrossRefGoogle ScholarPubMed
Grandi, G, De Fata, R, Varliero, F et al. Contemporary prescriptions pattern of different dose levonorgestrel-releasing intrauterine systems in an Italian service for family planning. Gynecol Endocrinol. 2020;36(12):1086–9.CrossRefGoogle Scholar
Ross, RK, Pike, MC, Vessey, MP et al. Risk factors for uterine fibroids: Reduced risk associated with oral contraceptives. BMJ. 1988;293:359–62.Google Scholar
Lethaby, AE, Cooke, I, Rees, M. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev. 2006:CD002126.CrossRefGoogle Scholar
Starczewski, A, Iwanicki, M. Intrauterine therapy with levonorgestrel releasing IUD of women with hypermenorrhea secondary to uterine fibroids. Ginekol Pol. 2000;71(9):1221–5.Google ScholarPubMed
Soysal, S, Soysal, ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: A prospective controlled trial. Gynecol Obstet Invest. 2005;59(1):29–35.CrossRefGoogle ScholarPubMed
Sayed, GH, Zakherak, MS, El-Nashar, SA et al. A randomized clinical trial of levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. International Journal of Gynecology and Obstetrics. 2011;112:126–30.CrossRefGoogle Scholar
Zapata, LB, Whiteman, MK, Tepper, NK et al. Intrauterine device use among women with uterine fibroids: A systematic review. Contraception. 2010;82:41–55.CrossRefGoogle ScholarPubMed
Marret, H, Fritel, X, Ouldamer, L et al. Therapeutic management of uterine fibroid tumors: Updated French guidelines. Eur J Obstet Gynecol Reprod Biol. 2012;165:156–64.CrossRefGoogle ScholarPubMed
Sletten, ET, Arnes, M, Vereide, AB et al. Low-dose LNG-IUS as therapy for endometrial hyperplasia: A prospective cohort pilot study. Anticancer Res. 2018;38(5):2883–9.Google ScholarPubMed
Whiteman, MK, Zapata, LB, Tepper, NK et al. Use of contraceptive methods among women with endometrial hyperplasia: A systematic review. Contraception. 2010;82(1):56–63.CrossRefGoogle ScholarPubMed
Coburn, SB, Bray, F, Sherman, ME et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451–60.CrossRefGoogle ScholarPubMed
Grimes, DA, Jones, LB, Lopez, LM et al. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 9:CD006134.Google Scholar
Holt, VL, Daling, JR, McKnight, B et al. Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol. 1992;79:529–33.Google Scholar
Grandi, G, Barra, F, Ferrero, S et al. Hormonal contraception in women with endometriosis: Asystematic review. Eur J Contracept Reprod Health Care. 2019;24(1):61–70.CrossRefGoogle Scholar
Grandi, G, Toss, A, Cortesi, L et al. The association between endometriomas and ovarian cancer: Preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int. 2015:751571.CrossRefGoogle Scholar
De Melo, AS, Dos Reis, RM, Ferriani, RA et al. Hormonal contraception in women with polycystic ovary syndrome: Choices, challenges, and noncontraceptive benefits. Open Access J Contraception. 2017;8:13–23.CrossRefGoogle ScholarPubMed
Charitidou, C, Farmakiotis, D, Zournatzi, V et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008:196(2):958–65.CrossRefGoogle ScholarPubMed
Bhattacharya, SM, Jha, A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053–9.CrossRefGoogle ScholarPubMed
Legro, RS, Arslanian, SA, Ehrmann, DA et al. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98:4565–92.CrossRefGoogle ScholarPubMed
Fauser, BC, Tarlatzis, BC, Rebar, RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM–Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.CrossRefGoogle ScholarPubMed
Conway, G, Dewailly, D, Diamanti-Kandarakis, E et al. The polycystic ovary syndrome: A position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014;171(4):P1–29.CrossRefGoogle ScholarPubMed
Li, J, Ren, J, Sun, W. A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2017;210:13–21.CrossRefGoogle ScholarPubMed
Del Savio, MC, De Fata, R, Facchinetti, F et al. Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: A new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–94.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×